EXO-CD24 as an add-on to standard of care therapy of ARDS patients has substantial beneficial clinical effects (oxygen saturation, respiratory rate), as well as improvements in biochemical parameters. The gene discussed is CD24; the disease is acute respiratory distress syndrome.